1. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
- Author
-
Zhang R, Yu Y, Hu S, Zhang J, Yang H, Han B, Cheng Y, and Luo X
- Subjects
- Animals, Anti-Inflammatory Agents pharmacology, Anti-Inflammatory Agents therapeutic use, Antioxidants metabolism, Antioxidants pharmacology, Antioxidants therapeutic use, Cytochrome P-450 CYP2E1 metabolism, Diet, High-Fat adverse effects, Dioxoles pharmacology, Dyslipidemias drug therapy, Dyslipidemias etiology, Dyslipidemias metabolism, Hypolipidemic Agents pharmacology, Hypolipidemic Agents therapeutic use, Inflammation blood, Inflammation etiology, Interleukin-6 blood, Lignans pharmacology, Lipid Metabolism genetics, Lipids blood, Lipogenesis drug effects, Lipogenesis genetics, Liver drug effects, Liver metabolism, Male, Non-alcoholic Fatty Liver Disease etiology, Non-alcoholic Fatty Liver Disease metabolism, Non-alcoholic Fatty Liver Disease pathology, Oxidative Stress drug effects, Phytotherapy, Plant Extracts pharmacology, Plant Extracts therapeutic use, Rats, Sprague-Dawley, Tumor Necrosis Factor-alpha blood, Dioxoles therapeutic use, Inflammation drug therapy, Lignans therapeutic use, Lipid Metabolism drug effects, Liver X Receptors metabolism, Non-alcoholic Fatty Liver Disease drug therapy, PPAR alpha metabolism, Sesamum chemistry
- Abstract
Nonalcoholic fatty liver disease (NAFLD) is defined by a nonalcohol relevant pathological accumulation of fat in the liver. Previous studies have shown that sesamin exerts antioxidant effects and improves lipid metabolism of the fatty liver. In this study, we hypothesized that sesamin improves lipid homeostasis of Sprague-Dawley rats fed a high-fat diet (HFD) by regulating the expression of genes related to de novo lipogenesis and β-oxidation. We induced NAFLD in rats with HFD and examined the effect of sesamin in vivo. The results showed that HFD rats accumulated total cholesterol and triacylglycerols in the liver and developed inflammation, as evidenced by the elevation of interleukin-6 and tumor necrosis factor-α in the liver and serum. Sesamin attenuated the disease progression by improving the blood lipid profile in a dose-dependent manner. Sesamin reduced the serum levels of total cholesterol, triacylglycerols, low-density lipoprotein cholesterol, and free fatty acid, whereas it increased the level of high-density lipoprotein cholesterol. Meanwhile, sesamin increased the activities of hepatic glutathione peroxidase and superoxide dismutase while reducing the level of malonaldehyde and cytochrome P450 2E1. Furthermore, higher doses of sesamin reduced the expression of liver X receptor α and its downstream target genes, whereas it upregulated the peroxisome proliferator-activated receptor α-mediated signaling. These findings suggest that sesamin attenuates diet-induced dyslipidemia and inflammation of NAFLD in rats via mechanisms regulated by liver X receptor α and peroxisome proliferator-activated receptor α., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF